Prediabetes includes impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) and there is a strong probability that prediabetes will lead to diabetes mellitus (DM). Serum fibroblast growth factor 21 (FGF-21) is known to increase as a compensatory response to metabolic imbalance under conditions such as obesity, metabolic syndrome, and DM. This study aimed to identify the relationship of serum FGF-21 to prediabetes and to biomarkers of related metabolic diseases. Three hundred five Korean adult patients participated in a cohort study from June 2012 to December 2015. Study subjects comprised of those with normal glucose tolerance(n=165), prediabetes(IFG, IGT, n=87) and type 2 diabetes(n=54). The biochemical parameters were analyzed using auto-analyzer, and the level of FGF-21 was estimated using an ELISA kit. The analysis revealed that FGF-21 levels were significantly higher in the Prediabetes group compared to those in the normal group(193.94±10.62, 343.49±60.94)(P=0.004). One-way ANCOVA was conducted on the correlations between serum FGF-21 levels and other parameters, dyslipidemia(F=7.428, P=0.007), HbA1c(F=11.874, P=0.001) was show statistical significance.

In conclusion, our results revealed that serum FGF-21 level serves as a marker predicting IFG.

Disclosure

H. Kim: None. H. Cho: None.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.